Page 261 - Haematologica Vol. 107 - September 2022

LETTER TO THE EDITOR
2011;29(22):3065-3071.
9. Pro B, Advani R, Brice P, et al. Five-year results of brentuximab
vedotin in patients with relapsed or refractory systemic
anaplastic large cell lymphoma. Blood. 2017;130(25):2709-2717.
10. Ginsberg S, Kirshner J, Reich S, et al. Systemic chemotherapy for a primary germ cell tumor of the brain: a pharmacokinetic
study. Cancer Treat Rep. 1981;65(5-6):477-483.
11. Ruf S, Hebart H, Hjalgrim LL, et al. CNS progression during
vinblastine or targeted therapies for high-risk relapsed ALK- positive anaplastic large cell lymphoma: a case series. Pediatr Blood Cancer. 2018;65(6):e27003.
12. Abid MB, Wang S, Loi HY, Poon LM. ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin. Ann Hematol. 2016;95(10):1725-1726.
13. Solomon BJ, Cappuzzo F, Felip E, et al. Intracranial efficacy of
crizotinib versus chemotherapy in patients with advanced ALK- positive non-small-cell lung cancer: results from PROFILE 1014. J Clin Oncol. 2016;34(24):2858-2865.
14. Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29(15):e443-445.
15. Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small- cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014;15(10):1119-1128.
16. Gambacorti-Passerini C, Mussolin L, Brugieres L. Abrupt relapse of ALK-positive lymphoma after discontinuation of crizotinib. N Engl J Med. 2016;374(1):95-96.
Haematologica | 107 September 2022
2260